[go: up one dir, main page]

MA55478A - Inhibiteurs bicycliques de hpk1 - Google Patents

Inhibiteurs bicycliques de hpk1

Info

Publication number
MA55478A
MA55478A MA055478A MA55478A MA55478A MA 55478 A MA55478 A MA 55478A MA 055478 A MA055478 A MA 055478A MA 55478 A MA55478 A MA 55478A MA 55478 A MA55478 A MA 55478A
Authority
MA
Morocco
Prior art keywords
bicyclic
hpk1 inhibitors
hpk1
inhibitors
bicyclic hpk1
Prior art date
Application number
MA055478A
Other languages
English (en)
Inventor
Christophe Denis Pascal Adelinet
Sophie Coupa
James Patrick Edwards
Laurence Anne Mevellec
Jorge Eduardo Vialard
Berthold Wroblowski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55478A publication Critical patent/MA55478A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA055478A 2019-03-26 2020-03-24 Inhibiteurs bicycliques de hpk1 MA55478A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962823712P 2019-03-26 2019-03-26
EP19167828 2019-04-08

Publications (1)

Publication Number Publication Date
MA55478A true MA55478A (fr) 2022-02-09

Family

ID=69845448

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055478A MA55478A (fr) 2019-03-26 2020-03-24 Inhibiteurs bicycliques de hpk1

Country Status (7)

Country Link
US (1) US20220169644A1 (fr)
EP (1) EP3947373A1 (fr)
AU (1) AU2020249397A1 (fr)
CA (1) CA3129772A1 (fr)
MA (1) MA55478A (fr)
TW (1) TW202102500A (fr)
WO (1) WO2020193512A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019373221B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP4303216A1 (fr) * 2021-03-03 2024-01-10 Genfleet Therapeutics (Shanghai) Inc. Composé hétérocyclique à six chaînons substitué par un cycle condensé, son procédé de préparation et son utilisation
CA3218194A1 (fr) * 2021-05-11 2022-11-17 Yuchuan Wu Compose heterocyclique contenant de l'azote
JP2024527623A (ja) 2021-07-20 2024-07-25 アストラゼネカ・アクチエボラーグ 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤
CN113861188B (zh) * 2021-08-23 2023-02-28 杭州医学院 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用
US20250011319A1 (en) * 2021-10-15 2025-01-09 Lomond Therapeutics, Inc. SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537929A (ja) 2014-12-05 2017-12-21 ジェネンテック， インコーポレイテッド Ｐｄ−１軸アンタゴニスト及びｈｐｋ１アンタゴニストを用いたがん治療のための方法及び組成物
SI3322711T1 (sl) 2015-06-25 2021-08-31 University Health Network Zaviralci HPK1 in postopek njihove uporabe
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
ES2927104T3 (es) * 2016-09-09 2022-11-02 Incyte Corp Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer
WO2018049191A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018081531A2 (fr) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Méthodess d'activation de lymphocytes t humains
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
JP7132937B2 (ja) 2017-03-15 2022-09-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１の阻害剤としてのアザインドール
RU2019133646A (ru) 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1
KR20190136028A (ko) 2017-03-30 2019-12-09 에프. 호프만-라 로슈 아게 Hpk1 억제제로서의 나프티리딘
EP3630778A1 (fr) 2017-05-26 2020-04-08 Ichnos Sciences SA Nouveaux inhibiteurs de map4k1
CA3079060A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Derives de pyrrolopyridine substitues utilises en tant que modulateurs de map4k1 pour le traitement de maladies cancereuses
CA3074381A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Derives de pyrrolopyridine substitues
WO2018228920A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)

Also Published As

Publication number Publication date
TW202102500A (zh) 2021-01-16
EP3947373A1 (fr) 2022-02-09
US20220169644A1 (en) 2022-06-02
CA3129772A1 (fr) 2020-10-01
AU2020249397A1 (en) 2021-09-30
WO2020193512A1 (fr) 2020-10-01

Similar Documents

Publication Publication Date Title
DK3956033T3 (da) Bicykliske forbindelser
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
MA55478A (fr) Inhibiteurs bicycliques de hpk1
DK3740479T3 (da) Dna-pk-hæmmere
AR119765A1 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
EP3833350A4 (fr) Inhibiteurs de pyrrolopyrimidine itk
MA52413A (fr) Inhibiteurs de cd73
MA52812A (fr) Inhibiteurs de sarm1
MA55909A (fr) Inhibiteurs de cdk
PT3746446T (pt) Inibidores de prc2
MA44006A (fr) Inhibiteur pde1
MA47301A (fr) Inhibiteurs sélectifs de jak1
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3938358A4 (fr) Inhibiteurs de rad51
EP3801500A4 (fr) Inhibiteurs de sarm1
EP3801499A4 (fr) Inhibiteurs de sarm1
MA55477A (fr) Inhibiteurs de hpk1
EP3786157A4 (fr) Inhibiteur de l'interaction protéine-protéine mll1-wdr5 de phényle triazole
EP4051688A4 (fr) Inhibiteurs de cd73
EP3919491A4 (fr) Inhibiteur d'akt
EP3999517A4 (fr) Inhibiteurs de cd73
MA53841A (fr) Inhibiteurs pde9 de pyrazolopyrimidine
MA51611A (fr) Inhibiteurs de pi4kiiibêta